We sought to test PARG inhibition in cancer cells and found that although existing PARG inhibitors (PARGi) have proven valuable29–31,36, issues with potency, bioavailability, rapid clearance, selectivity, or defined mechanism of action can cloud their applications for biology. The gene discussed is PARG; the disease is cancer.